Physician profile
Hungchih Lee
NPI 1881629764
$9,581.46
in general payments reported to CMS, 2019-2025
36 companies · $912 in 2025
The $912 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,928 · 2020: $1,391 · 2021: $1,721 · 2022: $1,269 · 2023: $1,237 · 2024: $1,122 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,164 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,163.93 |
| Education | $107.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,721.19 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $1,089.12 | 2020-2025 | Belbuca, Xtampza |
| Pfizer INC. | $971.93 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $710.88 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $672.63 | 2019-2025 | Relistor |
| Amgen INC. | $509.96 | 2019-2025 | Krystexxa |
| Daiichi Sankyo INC. | $411.46 | 2019 | |
| Assertio Therapeutics, INC. | $399.34 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $367.38 | 2020-2021 | |
| Lilly USA, LLC | $305.88 | 2019-2024 | Emgality, Reyvow |
| Biohaven Pharmaceuticals, INC. | $300.19 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $253.04 | 2019-2023 | Lyvispah |
| Almatica Pharma LLC | $242.03 | 2022-2023 | Gralise |
| Scilex Pharmaceuticals INC. | $204.02 | 2019-2020 | |
| Impel Pharmaceuticals INC. | $182.08 | 2023 | Trudhesa |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $151.23 | 2019-2020 | |
| Zyla Life Sciences, INC. | $130.21 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $129.73 | 2022 | |
| Protega Pharmaceutials INC | $109.59 | 2022-2023 | Roxybond |
| Medtronic, INC. | $102.68 | 2021-2024 | Intellis Adaptivestim |
| Boston Scientific Corporation | $74.42 | 2019 | |
| Merck Sharp & Dohme LLC | $73.23 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $66.66 | 2022-2023 | Quviviq |
| Tersera Therapeutics LLC | $59.10 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.00 | 2019 | |
| Eisai INC. | $53.48 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $52.84 | 2019-2024 | Austedo Xr |
| Lundbeck LLC | $32.66 | 2023-2025 | Vyepti |
| Forte Bio-Pharma LLC | $30.47 | 2024 | Prolate, Nalocet |
| Currax Pharmaceuticals LLC | $25.13 | 2019-2022 | |
| Averitas Pharma INC. | $18.37 | 2025 | Qutenza |
| Ibsa Pharma INC. | $15.94 | 2024 | Licart, Tirosint |
| Promius Pharma LLC | $15.78 | 2019 | |
| Globus Medical, INC. | $14.70 | 2025 | Senza |
| Avanir Pharmaceuticals, INC. | $13.03 | 2019 | |
| Grt US Holding, INC. | $12.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hungchih Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.